Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pregnant women and those who are planning pregnancy should not discontinue their medication without consulting a specialist, says a major new report from researchers at the University of Oxford.

Image courtesy of Shutterstock 

The latest Confidential Enquiry into Maternal Deaths and Morbidity from the national collaborative programme studying maternal and infant deaths, MBRRACE-UK, reviewed the care of 124 women who died and 46 women who had severe illness during or after pregnancy in the UK and Ireland between 2013 and 2015. The report, ‘Saving Lives, Improving Mothers’ Care’, examined the care of women with severe epilepsy and women who had severe mental illness, as well as the care of women who died. The authors identified that forward planning of care and optimising medication doses could make a major difference to women’s risk of complications.

The researchers noted that a number of women who died from epilepsy had stopped their medication early in pregnancy. In some instances this was because either they or their treating doctors were not aware that this could leave them and their unborn babies at increased risk from the effects of seizures. Women who consulted for specialist advice either before pregnancy or early in pregnancy and changed their medications where needed to those which were best for both them and their baby had the least complications in pregnancy. There is an urgent need to ensure women can access this specialist care.

Read more (University of Oxford website)

Similar stories

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.